AWM Investment Company Inc. Makes New $833,000 Investment in Capricor Therapeutics, Inc. $CAPR

Key Points

• AWM Investment Company Inc. has invested $833,000 in Capricor Therapeutics by acquiring 87,765 shares, representing approximately 0.19% ownership of the company.
• Capricor's stock performance has been volatile, with a one-year high of $23.40 and a low of $3.98, currently trading at $6.33.
• Analyst ratings for Capricor are predominantly positive, with a consensus rating of "Buy" and a target price of $22.56, despite recent earnings results that missed expectations.

AWM Investment Company Inc. bought a new position in shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 87,765 shares of the biotechnology company's stock, valued at approximately $833,000. AWM Investment Company Inc. owned 0.19% of Capricor Therapeutics as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in CAPR. Citizens Financial Group Inc. RI bought a new position in shares of Capricor Therapeutics in the 1st quarter worth about $95,000. ProShare Advisors LLC bought a new position in shares of Capricor Therapeutics in the 4th quarter worth about $142,000. Voya Investment Management LLC bought a new position in shares of Capricor Therapeutics in the 4th quarter worth about $150,000. Arizona State Retirement System bought a new position in shares of Capricor Therapeutics in the 1st quarter worth about $111,000. Finally, The Manufacturers Life Insurance Company increased its stake in shares of Capricor Therapeutics by 22.4% in the 4th quarter. The Manufacturers Life Insurance Company now owns 12,919 shares of the biotechnology company's stock worth $178,000 after acquiring an additional 2,361 shares in the last quarter. Hedge funds and other institutional investors own 21.68% of the company's stock.

Capricor Therapeutics Stock Performance

Shares of Capricor Therapeutics stock traded up $0.80 on Friday, hitting $6.74. 2,177,426 shares of the company traded hands, compared to its average volume of 1,395,168. The stock has a market capitalization of $308.15 million, a P/E ratio of -4.11 and a beta of 0.73. Capricor Therapeutics, Inc. has a 52 week low of $3.98 and a 52 week high of $23.40. The business has a 50-day simple moving average of $7.75 and a 200 day simple moving average of $10.11.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last released its quarterly earnings data on Monday, August 11th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.09). Capricor Therapeutics had a negative net margin of 181.71% and a negative return on equity of 62.71%. Research analysts expect that Capricor Therapeutics, Inc. will post -1.21 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on CAPR. B. Riley assumed coverage on shares of Capricor Therapeutics in a research note on Thursday, June 26th. They issued a "buy" rating and a $21.00 price target for the company. Alliance Global Partners reissued a "buy" rating on shares of Capricor Therapeutics in a research report on Monday, July 14th. Wall Street Zen lowered shares of Capricor Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Cantor Fitzgerald reissued an "overweight" rating and issued a $30.00 price objective on shares of Capricor Therapeutics in a report on Wednesday, May 14th. Finally, Oppenheimer decreased their target price on shares of Capricor Therapeutics from $43.00 to $22.00 and set an "outperform" rating on the stock in a research note on Monday, June 23rd. One investment analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company's stock. According to MarketBeat, Capricor Therapeutics has an average rating of "Buy" and an average price target of $22.56.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.